Sanofi and Exscientia establish strategic research collaboration
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
List view / Grid view
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
A research team based at Skoltech in Russia has developed an artificial intelligence-driven solution for highly accurate detection of efficacious binding sites to expedite drug discovery.
12 January 2022 | By Thermo Fisher Scientific
Explore new methods and software enhancements to support your bioanalytical workflows by watching this on-demand webinar.
News from the Pasteur Institute in France reports on how multi organisational efforts of numerous research institutes enabled the scientific community to gain key insight into the Omicron variant, facilitating a rapid life-saving response.
A new platform, named Virtual Synthon Hierarchical Enumeration Screening, has been developed by researchers to efficiently discover drugs.
In this Q&A, Professor Ross King from the University of Cambridge, UK, discusses how a new machine learning approach could aid drug discovery and development. The method learns from multiple problems and improves performance while it learns.
A new study in the US has used a computer model to reveal the mechanism of action of lipoprotein-associated phospholipase A2 – a biomarker for cardiovascular disease.
4 January 2022 | By SomaLogic
Watch our on-demand one-hour session to discover groundbreaking work to advance precision medicine for Castleman disease.
With a range of tools available to scientists in the field of therapeutic discovery and development, flow cytometry presents an advantageous method to sort cells based on subtle differences. To find out more, Drug Target Review’s Victoria Rees spoke with Dr Peter O’Toole, Head of Imaging and Cytometry and Dr…
In this podcast, join Tyler Pascoe and Matt Gruver from Thermo Fisher Scientific as they explore the new Watson LIMS software.
A microplate-based method for the determination of association and dissociation rate values in high throughput using a kinetic probe competition assay (kPCA).
This issue includes articles that discuss the development of long-term 3D tissue cultures from human biopsy samples, the application of flow cytometry in drug discovery and automation for upstream processing in a biologics manufacturing environment. Also included are features on informatics, proteomics and CRISPR.
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.
Transformational machine learning (TML) learns from multiple problems and improves performance while it learns, potentially accelerating drug discovery.
With an ever-increasing emphasis on minimising drug candidate attrition, scientists are focusing on target safety at earlier points in the research process. In this exclusive interview, Drug Target Review spoke with Dr Gordon Baxter, Chief Scientific Officer of Instem, to learn how target safety assessments can enable researchers to quickly…